We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | NASDAQ:VRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.62 | -1.65% | 395.52 | 395.80 | 403.50 | 404.07 | 398.46 | 402.95 | 1,050,648 | 00:55:03 |
From May 2019 to May 2024
By Chris Wack
Vertex Pharmaceuticals Inc. said Friday the U.S. Food and Drug Administration approved Kalydeco ivacaftor for use in children with cystic fibrosis ages four months to less than six months old.
The company said Kalydeco is already approved in the U.S. and EU for the treatment of CF in patients ages six months and older.
Vertex said this FDA approval is based on data from a cohort in the 24-week Phase 3 open-label safety cohort consisting of six children with CF ages four months to less than six months who have one of 10 mutations in the CFTR gene. This cohort demonstrated a safety profile similar to that observed in older children and adults.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 25, 2020 08:29 ET (12:29 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Vertex Pharmaceuticals Chart |
1 Month Vertex Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
